Next Generation of Stents Responds to Problems

Newer drug-eluting and biodegradable versions show promise

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Alzheimer's Disease • Aneurysms • Angina Pectoris • Angiogram More... Related Healthscout Videos Howard: The Helping Hand for Stroke Survivors Fixing Torn Hearts Medicine's Next Big Thing? Growing Hearts How can a supportive family help? More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Coronary Bypass Surgery • Erectile Dysfunction More... Related Drug Information • Accupril • Actonel • Altace • Avapro More... Related News Articles • Pacemakers Change Biology of the Heart • Lack of Sleep Hurts Women's Hearts Most • More Seniors Falling Victim to Escalator Injuries • Gene Linked to Form of Parkinson's Disease More...

SATURDAY, March 24 (HealthDay News) -- A new generation of stents, created largely to address problems associated with the current artery-opening devices, made their debut during the American College of Cardiology meeting in New Orleans Saturday.

These new stents attempt to ward off restenosis, the reclosing of a stented vessel, and thrombosis, the dangerous clotting that has been seen mostly in drug-eluting stents. The innovations ranged from coating stents with different and better drugs to building biodegradable stents that dissolve over time.

Text Continues Below

---

In one study, researchers compared the standard paclitaxel-eluting stent with a new drug-eluting stent called Xience V. Dr. Gregg W. Stone, director of Cardiovascular Research and Education at Columbia University Medical Center, and his colleagues randomly assigned 1,002 patients to receive stents with either Xience V or the standard drug-eluting stent.

"This is a second-generation drug-eluting stent," Stone said. "This trial was designed to get approval for this stent in the United States."

Stone's team found that after nine months, patients treated with the newer stent had similar rates of failure in the treated blood vessel, but needed fewer new procedures. There were fewer major cardiac events at nine months among patients treated with the XIENCE V compared with the standard drug-eluting stent (4.6 percent vs. 8.1 percent).

The new stent also decreased blood vessel loss and tended to reduce the re-blocking of the treated arteries compared with the standard drug-eluting stent (4.7 percent vs. 8.9 percent), Stone's group reported.

"This stent is at least as safe and effective and, for several of the important endpoints, is superior to the standard drug-eluting stent," Stone said.

Two other studies presented at the meeting by teams of Dutch researchers were on the cutting edge of stent development.

Page:  1 | 2 | 3 | Next >>